| |
Patients with liver metastases n = 69 (cases)
|
Patients without liver metastases n = 70 (cases)
|
pvalue
|
---|
Gender
|
M/F
|
40/29
|
38/32
|
N.S.
|
Age
|
Years
|
60.7 ± 9.9
|
62.5 ± 10.1
|
N.S.
|
TNM stage
|
I/II/III/IV
|
0/12/23/34
|
11/38/21/0
|
< 0.01a
|
Tumour site
|
C/R
|
45/24
|
49/21
|
N.S.
|
LN mets
|
Yes/No
|
41/28
|
31/39
|
N.S.
|
Differentiation
|
w/mod/por
|
37/30/2
|
21/33/16
|
N.S.
|
Liver mets
|
Sync/Meta
|
23/46
|
N.A.
|
N.A.
|
No. of liver mets
|
Solo/Multi
|
38/31
|
N.A.
|
N.A.
|
PTEN expression
|
S/W
|
17/52
|
44/26
|
< 0.01a
|
Median follow-up
|
Months
|
35.5 ± 27.4
|
37.2 ± 39.9
|
N.S.
|
5-year survival
|
(%)
|
34.3
|
79.2
|
< 0.01b
|
- LN, lymph node; mets, metastasis; M, male; F, female; C, colon; R, rectum; w, well differentiated adenocarcinoma; mod, moderately differentiated adenocarcinoma; por, poorly differentiated adenocarcinoma; Sync, synchronous metastasis; Meta, metachronous metastasis; Solo, solitary metastasis; Multi, multiple metastases; S, strong; W, weak; N.A., not applicable; N.S., not significant. The a p-values were obtained using the Mann-Whiteny U test. The b p-values were obtained using Kaplan-Meier survival curves based on PTEN expression tested with the Wilcoxon test. Values of age are given mean ± s.d. N.S., not significant.